Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L7 pseudogene 51 (RPL7P51) is a **processed pseudogene copy** of the functional RPL7 gene, which encodes a structural component of the large 60S subunit of eukaryotic ribosomes[1][6]. Unlike the parent gene, RPL7P51 is classified as a pseudogene—meaning it is not believed to produce a functional protein and is not part of the protein-coding genome[6]. Pseudogenes such as RPL7P51 are commonly formed by retrotransposition or duplication events and do not possess biological activity. There are **numerous processed pseudogenes for ribosomal proteins throughout the genome**, and most are not transcribed or translated[6][7]. RPL7P51 is not considered a therapeutic target, biomarker, or relevant druggable molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7 pseudogene 51 (RPL7P51).